Kangtai Drops Plan for China Vaccine JV With AstraZeneca

 
• By Dexter Jie Yan
  
Seal terminated stamped on a document and fountain pen. Macro shot. Soft focus.
Kangtai decides to terminate plan for roughly $400m China vaccine JV with AstraZeneca • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business